In non-small-cell lung cancer (NSCLC), tumor mutation burden (TMB) and the expression status of PD-L1 have been reported to be predictive factors of ICI treatment [8,9,10]; however, in contrast to the findings for NSCLC, previous studies showed that neither TMB nor PD-L1 expression status could predict the efficacy of ICI treatment for ED-SCLC [4,11,12]. Here, CD274 is linked to neoplasm.